Replies to post #369312 on Anavex Life Sciences Corp (AVXL)

[hnbadger1]

If another P3 is required, there will be a lot of P/O’d share holders because Anavex took a big gamble and set approval back 3-4 years.
Maybe the thinking was that PDD has a 70% correlation with AD so that would qualify. However, for what ever reason, they sat on the PDD data for two years.

I’m still trying to believe in TGD’s quote “when it’s over, you will see why we did what we did “ but I must admit, it’s getting harder to believe.
Why sit on PD/PDD data for two years?
Why is it taking a year and a half to recruit a handful of Rett girls?

Why has Fragile x been promised for two years?
Why so long on the mystery rare indication?
I read that SAVA recruited 300 trial patients rather quickly.
Is the precision medicine focus really worth the years of additional time?

[crescentmotor]

This is why realistic buyout or partnership is the best option imo

AVXL was always destined to need a partner for the large indications. If the AD readouts are positive, I think that will be a good time to get serious about a partner with some up-front money, especially with more trials for PD, PDD, and likely AD, whether the AD trial be a Phase 4 confirmatory or another Phase 3